Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
DNLI Analyst Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DNLI Stock 12 Month Forecast
Average Price Target
$32.88
▲(100.73% Upside)
| Highest Price Target$40.00 | Average Price Target$32.88 | Lowest Price Target$27.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$32
Buy
95.36%
Upside
Reiterated
10/14/25
Stifel Nicolaus
$37
Buy
125.89%
Upside
Reiterated
10/14/25
Wedbush
$30
Buy
83.15%
Upside
Reiterated
10/14/25
Oppenheimer
$35
Buy
113.68%
Upside
Reiterated
10/14/25
William Blair
―
Buy
―
Reiterated
10/13/25
J.P. Morgan
―
Buy
―
Reiterated
10/13/25
Bank of America Securities
$27
Buy
64.84%
Upside
Reiterated
10/13/25
Denali Therapeutics: Buy Rating Maintained Amid Strategic Developments and FDA CollaborationWe spoke with management including CEO Ryan Watts who indicated the extension was triggered by a request for updated pharmacological data related to a 5% discrepancy in the theoretical molecular weight of Tivi’. This request was classified as a Major Amendment (MA). The company noted they have already submitted all information requested by the agency. Importantly, management emphasized that this issue is not related to manufacturing, but rather a specific clinical pharmacology data request. The extension came as a surprise to the company (and to us given their general positive view of the review at our recent West Coast bus tour stop, see report), but they noted the FDA has been highly collaborative and engaged in the review process. DNLI reiterated that the amendment is not indicative of concerns around approvability.
Cantor Fitzgerald
―
Buy
―
Reiterated
09/08/25
Morgan Stanley
$33→$30
Buy
83.15%
Upside
Reiterated
08/18/25
BTIG
$32
Buy
95.36%
Upside
Reiterated
08/17/25
Leerink Partners
$40
Buy
144.20%
Upside
Reiterated
08/13/25
TD Cowen
―
Buy
―
Reiterated
08/11/25
Robert W. Baird
$30→$29
Buy
77.05%
Upside
Reiterated
05/08/25
B. Riley Securities
$35→$30
Buy
83.15%
Upside
Reiterated
05/08/25
Deutsche Bank
$31
Buy
89.26%
Upside
Initiated
02/11/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$32
Buy
95.36%
Upside
Reiterated
10/14/25
Stifel Nicolaus
$37
Buy
125.89%
Upside
Reiterated
10/14/25
Wedbush
$30
Buy
83.15%
Upside
Reiterated
10/14/25
Oppenheimer
$35
Buy
113.68%
Upside
Reiterated
10/14/25
William Blair
―
Buy
―
Reiterated
10/13/25
J.P. Morgan
―
Buy
―
Reiterated
10/13/25
Bank of America Securities
$27
Buy
64.84%
Upside
Reiterated
10/13/25
Denali Therapeutics: Buy Rating Maintained Amid Strategic Developments and FDA CollaborationWe spoke with management including CEO Ryan Watts who indicated the extension was triggered by a request for updated pharmacological data related to a 5% discrepancy in the theoretical molecular weight of Tivi’. This request was classified as a Major Amendment (MA). The company noted they have already submitted all information requested by the agency. Importantly, management emphasized that this issue is not related to manufacturing, but rather a specific clinical pharmacology data request. The extension came as a surprise to the company (and to us given their general positive view of the review at our recent West Coast bus tour stop, see report), but they noted the FDA has been highly collaborative and engaged in the review process. DNLI reiterated that the amendment is not indicative of concerns around approvability.
Cantor Fitzgerald
―
Buy
―
Reiterated
09/08/25
Morgan Stanley
$33→$30
Buy
83.15%
Upside
Reiterated
08/18/25
BTIG
$32
Buy
95.36%
Upside
Reiterated
08/17/25
Leerink Partners
$40
Buy
144.20%
Upside
Reiterated
08/13/25
TD Cowen
―
Buy
―
Reiterated
08/11/25
Robert W. Baird
$30→$29
Buy
77.05%
Upside
Reiterated
05/08/25
B. Riley Securities
$35→$30
Buy
83.15%
Upside
Reiterated
05/08/25
Deutsche Bank
$31
Buy
89.26%
Upside
Initiated
02/11/25
Best Analysts Covering Denali Therapeutics
1 Month
xxx
Success Rate
11/14 ratings generated profit
Average Return
+8.34%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 78.57% of your transactions generating a profit, with an average return of +8.34% per trade.
3 Months
xxx
Success Rate
10/17 ratings generated profit
Average Return
+14.66%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +14.66% per trade.
1 Year
Success Rate
9/17 ratings generated profit
Average Return
+15.41%
reiterated a buy rating 18 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +15.41% per trade.
2 Years
xxx
Success Rate
7/18 ratings generated profit
Average Return
-4.08%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 38.89% of your transactions generating a profit, with an average return of -4.08% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DNLI Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
11
13
8
8
12
Buy
5
3
3
4
5
Hold
2
0
0
0
0
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
16
11
12
17
Each month's total comprises the sum of three months' worth of ratings.
DNLI Financial Forecast
DNLI Stock Forecast FAQ
What is DNLI’s average 12-month price target, according to analysts?
Based on analyst ratings, Denali Therapeutics’s 12-month average price target is 32.88.
What is DNLI’s upside potential, based on the analysts’ average price target?
Denali Therapeutics has 100.73% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DNLI a Buy, Sell or Hold?
Denali Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Denali Therapeutics’s price target?
The average price target for Denali Therapeutics is 32.88. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $27.00. The average price target represents 100.73% Increase from the current price of $16.38.
The highest analyst price target is $40.00 ,the lowest forecast is $27.00. The average price target represents 100.73% Increase from the current price of $16.38.
What do analysts say about Denali Therapeutics?
Denali Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of DNLI?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.